(UNIVERSITY OF WASHINGTON HEALTH SCIENCES/UW MEDICINE) According to a recent press release, the virus that causes hepatitis C protects itself by blocking signals that call up immune defenses in liver cells, according to University of Washington researchers and colleagues reporting Nov. 14 in Nature Medicine.
(UNIVERSITY OF LEEDS) According to a recent press release, a virus that causes childhood coughs and colds could help in the fight against primary liver cancer, according to a study. Reovirus stimulates the body’s own immune system to kill off the cancerous cells, the researchers at the University of Leeds found. In addition, Reovirus is able […]
(PR Newswire) According to a recent press release, two injections of RG-101, in combination with a four-week course of direct-acting antiviral (DAA) therapy, has been shown to clear hepatitis C in patients at both 12 and 24 weeks after treatment in the majority of patients, according to research presented this week at The Liver Meeting® […]
(PR Newswire) AbbVie recently announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for the investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P) for the treatment of patients with chronic hepatitis C virus (HCV) who failed previous therapy with direct-acting antivirals (DAAs) in genotype 1 (GT1), including therapy with […]